Messenger RNA (mRNA) therapeutics have revolutionized the landscape of modern medicine, offering unprecedented opportunities for tackling a wide spectrum of diseases, from infectious pathogens to genetic disorders. However, despite the remarkable success of initial mRNA vaccines, a persistent hurdle remains: how to achieve sustained and efficient in vivo protein expression while simultaneously minimizing immune system activation. This challenge is crucial, as unwanted innate immune responses can undermine therapeutic efficacy and safety. A groundbreaking study by Kim et al., published in Gene Therapy in 2026, addresses this bottleneck head-on with the development of CJ-1, an innovatively engineered mRNA platform designed for optimized regulation and minimal immunogenicity.
At the heart of CJ-1’s design lies the meticulous optimization of the mRNA’s major regulatory elements, including the 5′ untranslated region (UTR), the 3′ UTR, and the poly (A) tail – components that are pivotal in controlling mRNA stability, translational efficiency, and immunogenicity. The researchers undertook a systematic approach to fine-tune these regions, balancing the structural elements that promote robust protein production against molecular features that typically trigger innate immune sensors. By doing so, they generated an mRNA construct with markedly improved performance profiles compared to first-generation mRNA therapies currently in use.
Experimental validation of CJ-1 was thorough and multifaceted. In vitro studies across a variety of mammalian cell lines revealed that CJ-1 consistently delivers superior protein expression levels relative to benchmark mRNA constructs. This enhanced expression is attributed to improved translational initiation and increased mRNA half-life, conferred by the engineered untranslated regions. Moreover, this heightened efficacy was not limited to isolated cell cultures; in vivo experiments in mouse models corroborated the robust expression potential of CJ-1, demonstrating sustained protein production over extended periods following administration.
One of the most striking findings of the study is CJ-1’s ability to evade innate immune recognition more effectively than traditional mRNA constructs. Where many mRNA therapies have struggled with triggering inflammatory cytokine cascades—limiting repeat dosing and raising safety concerns—CJ-1 elicited significantly lower cytokine responses in both in vitro immune cell assays and in vivo murine experiments. This reduced immunogenicity is a critical advancement, potentially allowing higher therapeutic dosages and minimizing adverse immune events that can compromise therapeutic outcomes.
To explore CJ-1’s practical therapeutic potential, the research team encoded erythropoietin (EPO), a clinically relevant protein for treating anemia, into the optimized mRNA scaffold. They encapsulated the EPO-mRNA within a Pfizer-BioNTech lipid nanoparticle (LNP) formulation, a clinically validated delivery vehicle known for its efficient cellular uptake and protection of mRNA cargo. When administered intraperitoneally in mice, this formulation induced elevated and sustained serum levels of EPO, validating the functional translation of the optimized transcript in vivo.
More importantly, the biological activity of expressed EPO was confirmed through physiologically relevant endpoints. Mice treated with CJ-1 based EPO mRNA showed significant increases in reticulocyte counts and hematocrit levels, markers of enhanced red blood cell production. This observation not only suggests effective protein synthesis but also confirms that the synthesized protein retains its full bioactivity. These results validate CJ-1’s potential for therapeutic application, especially in diseases requiring sustained protein replacement or supplementation.
The CJ-1 study exemplifies how modular engineering of mRNA regulatory elements can transcend conventional limitations of mRNA therapeutics. The 5′ and 3′ UTRs, often overlooked outside of coding sequence design, play fundamental roles in ribosome recruitment, mRNA secondary structure stability, and interaction with RNA-binding proteins and microRNAs. Similarly, poly (A) tail length modulates mRNA stability and translation efficiency. Through a combination of computational modeling, high-throughput screening, and functional assays, the authors optimized these elements to achieve a fine balance—maximizing expression while mitigating immunogenic signals.
One cannot overstate the importance of immunogenicity control in clinical translation. The innate immune system senses foreign RNA primarily through pattern recognition receptors such as Toll-like receptors (TLR7/8), RIG-I-like receptors, and the inflammasome complex. Excessive activation of these pathways results in inflammation, interferon production, and cytotoxicity, which can blunt therapeutic effects and lead to side effects. CJ-1’s refined structure appears to circumvent these pathways more effectively than previous constructs, as confirmed by lower cytokine release profiles. This property might enable chronic or repeated dosing regimens, essential for treating chronic or genetic diseases with protein replacement therapies.
The use of clinically relevant delivery systems like Pfizer-BioNTech LNPs further enhances the translational appeal of CJ-1. These nanoparticles facilitate efficient delivery, protect mRNA from extracellular degradation, and optimize biodistribution. The successful in vivo delivery and expression of EPO using this platform not only validate CJ-1’s compatibility with existing clinical-grade formulations but also pave the way for rapid adoption in diverse therapeutic contexts, from rare diseases to cancer immunotherapy.
CJ-1’s versatility also extends across cell types, demonstrated by broad-spectrum applicability in multiple cell lines. This feature is highly desirable, as different tissues and disease states pose unique challenges for mRNA expression. The ability of CJ-1 to maintain high protein output and low immunogenicity across diverse biological environments suggests its promise as a universal platform technology adaptable for a variety of therapeutic proteins and targets.
The implications of this work for the future of mRNA medicine are profound. By resolving the dual challenges of expression efficiency and immunogenicity, CJ-1 offers a blueprint for the next generation of mRNA therapeutics that can overcome current clinical barriers. Whether for vaccine development, enzyme replacement therapy, or gene editing applications, such an optimized platform can dramatically accelerate progress and improve patient outcomes.
Further research will undoubtedly explore the scalability and long-term safety of CJ-1-based therapeutics in larger animal models and human clinical trials. Studies may also delve into combining CJ-1 with novel mRNA modifications and delivery innovations to further enhance performance. Integration with personalized medicine approaches could customize untranslated region designs tailored for individual patient needs or disease states.
In conclusion, the development of CJ-1 stands as a landmark in synthetic biology and therapeutic mRNA engineering. The platform’s enhanced protein expression profile coupled with minimal immune activation potential addresses key impediments that have limited the broader applicability of mRNA drugs. This innovation marks a significant advance toward safer, more effective mRNA-based therapies that hold promise to transform how a multitude of diseases are managed in the near future.
Researchers and clinicians alike will watch closely as CJ-1 progresses through preclinical development and into human trials. Its advantages over first-generation mRNA platforms might well establish new standards for designing RNA therapeutics, setting the stage for a new era where protein production from mRNA is not only potent but also exquisitely controlled and safe. The synthesis of bioengineering precision and immunological insight embodied by CJ-1 hints at an exciting and expanding frontier in molecular medicine.
Subject of Research:
Development and optimization of an mRNA platform (CJ-1) with enhanced protein expression and reduced innate immunogenicity for therapeutic protein production.
Article Title:
CJ-1: an optimized mRNA platform with enhanced protein expression and minimal immunogenicity for therapeutic applications.
Article References:
Kim, S., Jo, M.J., Jeong, M.S. et al. CJ-1: an optimized mRNA platform with enhanced protein expression and minimal immunogenicity for therapeutic applications. Gene Ther (2026). https://doi.org/10.1038/s41434-026-00606-4
Image Credits: AI Generated
DOI:
13 March 2026
Tags: 3′ untranslated region engineering5′ untranslated region optimizationCJ-1 mRNA platformgene therapy advancementsinnate immune response minimizationmRNA stability enhancementmRNA translational efficiencynext-generation mRNA vaccinesoptimized mRNA therapeuticspoly(A) tail modificationreduced mRNA immunogenicitysustained in vivo protein expression
